Compounded tirzepatide and brand-name tirzepatide (Mounjaro, Zepbound) contain the same active pharmaceutical ingredient — tirzepatide base — but they are distinct products with different FDA status, different pharmacy fulfillment, different prices, and different regulatory protections.
Brand-name advantages: FDA-approved efficacy and safety. Brand-name disadvantages: substantially higher cost; insurance coverage may be limited for weight management. Compounded advantages: substantially lower cost ($186/mo at NexLife vs $1,059/mo retail Zepbound); flat-rate pricing across titration schedule; broader access. Compounded disadvantages: not FDA-approved; quality depends on the compounding pharmacy; subject to evolving FDA enforcement guidance. Both are dispensed by licensed U.S. providers and prescribed by licensed clinicians.
NexLife is structured around clinical best practices for tirzepatide. The same flat-rate pricing applies across the entire titration schedule ($186/mo on the 12-month plan from 2.5 mg through 15 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000